Vaxcyte (PCVX) Amortization of Deferred Charges (2021 - 2026)
Vaxcyte (PCVX) posted quarterly Amortization of Deferred Charges of $2.9 million for Q1 2026, up 51.56% year-over-year from $1.9 million in Q1 2025, and up 26.23% quarter-over-quarter from $2.3 million in Q4 2025.
Vaxcyte (PCVX) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Amortization of Deferred Charges for 6 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 51.56% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $9.5 million (up 9.06% YoY), while the FY2025 annual figure was $8.5 million, down 4.28% from the prior year.
- Amortization of Deferred Charges advanced to $2.9 million in Q1 2026 per PCVX's latest filing, from $2.3 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.9 million in Q1 2026 and bottomed at $1.6 million in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $2.0 million across 5 years, with a median of $1.9 million in 2024.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges surged 892.78% — and 2025, when it decreased 21.09%.
- Vaxcyte's Amortization of Deferred Charges stood at $1.6 million in 2022, then gained by 28.91% to $2.1 million in 2023, then dropped by 6.75% to $1.9 million in 2024, then grew by 19.89% to $2.3 million in 2025, then gained by 26.23% to $2.9 million in 2026.
- Business Quant data shows PCVX's Amortization of Deferred Charges at $2.9 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.92 Mn |
| Jun 30, 2026 | 2.92 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Mar 31, 2026 | 2.91 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |